META-ANALYSIS

The diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in COVID-19: a systematic review and meta-analysis

Ahmed Abdelaal Ahmed Mahmoud M. Alkhatip a,b,c, Mohamed Gomaa Kamel d,e, Mohamed Khaled Hamza d, Ehab Mohamed Farag d, Hany Mahmoud Yassin d, Mohamed Elayashy d, Amr Ahmed Naguib d, Mohamed Wagihi d, Fatma Abd-Elshahed Abd-Elhay d, Haytham Zien Algameel f, Mohammed A. Yousef g, Andrew Purcell h and Mohamed Helmy d

*Department of Anaesthesia, Birmingham Children’s Hospital, Birmingham, UK; bDepartment of Anaesthesia, Beni-Suef University Hospital and Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt; cFaculty of Medicine, Minia University, Minia, Egypt; dDepartment of Anaesthesia, Faculty of Medicine, Cairo University, Cairo, Egypt; eDepartment of Anaesthesia, Faculty of Medicine, Fayoum University, Fayoum, Egypt; fDepartment of Anaesthesia, Aberdeen Royal Infirmary Hospital, Aberdeen, UK; gDepartment of Anaesthesia, IABF Hospital, Dammam, Saudi Arabia; hDepartment of Anaesthesia, Beaumont Hospital, Dublin, Ireland

ABSTRACT

Background: The world urgently requires surrogate markers to diagnose COVID-19 and predict its progression. The severity is not easily predicted via currently used biomarkers. Critical COVID-19 patients need to be screened for hyperinflammation to improve mortality but expensive cytokine measurement is not routinely conducted in most laboratories. The neutrophil-to-lymphocyte ratio (NLR) is a novel biomarker in patients with various diseases. We evaluated the diagnostic and prognostic accuracy of the NLR in COVID-19 patients.

Methods: We searched for relevant articles in seven databases. The quantitative analysis was conducted if at least two studies were evaluating the NLR role in COVID-19.

Results: We included 8,120 individuals, including 7,482 COVID-19 patients, from 32 articles. Patients with COVID-19 had significantly higher levels of NLR compared to negative individuals. Advanced COVID-19 stages had significantly higher levels of NLR than earlier stages.

Expert Opinion: We found significantly higher levels of NLR in advanced stages compared to earlier stages of COVID-19 with good accuracy to diagnose and predict the disease outcome, especially mortality prediction. A close evaluation of critical SARS-CoV-2 patients and efficient early management are essential measures to decrease mortality. NLR could help in assessing the resource allocation in severe COVID-19 patients even in restricted settings.

1. Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, a.k.a. COVID-19) is now much more hazardous than previously thought when compared to other viral pandemics. The H1N1 pandemic outbreak of 2009 caused 12,429 deaths over a year while the SARS-CoV-2 outbreak resulted in >13,000 over 5 weeks in the USA alone[1]. SARS-CoV-2 may present as a mild disease with interstitial and alveolar pneumonia; however, it can affect other organs, such as the kidneys, heart, digestive tract, and nervous system [2–5]. There are no specific antiviral therapies or vaccines for COVID-19 patients. Consequently, researchers started to use clinically accessible interventions utilized previously during SARS-CoV and the Middle East respiratory syndrome-coronavirus (MERS-CoV) outbreaks due to their genetic and clinical similarities [6].

Because of the rapid spread of the pandemic, the world urgently requires surrogate markers to diagnose COVID-19 infection. Perhaps as importantly, markers that help predict disease progression and severity are needed to help identify high-risk individuals in efforts to ensure optimal resource allocation in a time of significant resource demand. Effective predictors could also help screening, clinical management, and prevention of fatal sequelae. Indeed, critical COVID-19 status is not easily predicted via routinely used laboratory parameters including levels of platelets, eosinophil, hemoglobin, D-dimer, IL-6, lactate dehydrogenase, prothrombin time, activated partial thromboplastin time and transaminases [7–12]. Further, patients with severe COVID-19 infection need to
be screened for hyper-inflammatory status using laboratory biomarkers in efforts to improve morbidity and mortality since numerous studies suggest that a subgroup of critical COVID-19 infected patients could have immune dysregulation potentially contributing to the development of a virally induced hyper-inflammatory state [13]. Expensive cytokine profile measurement is not routinely performed in most laboratories and is needed to identify patients who would potentially benefit from anti-IL6 immunotherapies with tocilizumab [7]. In contrast, routine full blood count and white cell differentials are readily available and performed across the vast majority of healthcare settings caring for COVID-19 infected patients. Therefore, reliable markers of infection such as neutrophil-to-lymphocyte ratio (NLR), associated with IL-6, could be considered valuable in efforts to help diagnosis and prognosis.

The NLR, an inflammatory index reflecting systemic inflammatory cascades, is a novel biomarker in patients with pneumonia, various cardiovascular diseases, sepsis, multiple organ damage, cancer, and pregnancy complications [14–21]. Accumulated evidence has shed light on the pivotal diagnostic and prognostic role of NLR in infections. Han and coworkers demonstrated that NLR had better accuracy compared to the total leukocyte count, neutrophil or lymphocyte count and is used as an efficient diagnostic measure to screen individuals infected with influenza virus [22] because it is less influenced by physiological interference such as that seen with dehydration or physical activity. In addition, NLR has been measured and used to forecast recurrence in those with hepatitis B [23]. A comprehensive analysis of all published studies has not been conducted yet to investigate the estimated accuracy of NLR in the context of COVID-19 infections although several studies revealed its findings from routine blood tests in severe and non-severe COVID-19 patients. With this in mind, this systematic review and meta-analysis aimed to investigate the diagnostic and prognostic accuracy of the NLR in COVID-19 patients.

2. Methods

2.1. Search strategy

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplemental File 1) [24]. The protocol was registered on the International Prospective Register of Systematic Reviews PROSPERO (CRD42020201117). In July 2020, we conducted an electronic search to acquire pertinent studies on the following databases: PubMed, Embase, Institute of Science Index, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL). Pre-specified search terms were utilized and adapted to each database to yield the most accurate results (Supplementary File 2). Moreover, the references from relevant studies and previous reviews were manually searched. Furthermore, Chinese databases such as Wanfang as well as China National Knowledge Infrastructure databases were searched. Three reviewers independently screened titles and abstracts according to our inclusion and exclusion criteria and any disagreements were resolved through discussion.

2.2. Selection criteria

The inclusion criteria were studies investigating the diagnostic and/or prognostic role of NLR in COVID-19 patients against the reference standard (polymerase chain reaction (PCR) test). Any original studies including clinical trials and observational studies with no restrictions regarding language, race, sex, country, year, and age were included. Our exclusion criteria were overlapped data sets and duplicated studies. Articles such as animal studies, case reports, previous reviews, conference, books, or thesis or author responses which do not have enough information to be extracted were excluded. Included studies were required to have a two-by-two table for the analysis constructed from the reported information, raw data, or sensitivity, and specificity of the NLR. We contacted the authors if these values were not reported. All full texts were reviewed carefully by three independent reviewers and where there was any disagreement it was resolved through discussion to reach a final decision.

2.3. Outcomes and extracted data

A standardized data extraction sheet was produced in Microsoft Excel. The data were extracted by three independent authors. The discussion was held if there were any disagreements. Conclusions were drawn with the consensus of the three authors or, if needed, discussed with a fourth author. Papers published by the same research group and/or studying the same outcomes were examined for potential duplicate information based on the month and year of patients’ recruitment and hospital where the patients were recruited and confirmation from authors of the study. The extracted information included the authors’ names, study design, year, number of patients, hospital, and country. Moreover, patients’ demographics (such as age and gender), the cutoff value of NLR and the definition of the different groups such as severe COVID-19 patients were extracted.

Our primary outcome was to determine the diagnostic and/or prognostic accuracy of NLR in COVID-19 patients whereas our secondary outcome was to compare the values of NLR in different groups (control individuals versus mild, moderate, severe, and lethal COVID-19 infections).

2.4. Quality assessment

We used the quality assessment of diagnostic accuracy studies (QUADAS-2) method. The QUADAS-2 evaluates four items for bias and applicability of the research question including patients’ selection, index test, reference standard, and flow and timing [25]. The quality of the included studies was evaluated by three authors independently and if any disagreement occurred, it was resolved through discussion.

2.5. Statistical analysis

The quantitative analysis was conducted if at least two studies were evaluating the role of NLR in COVID-19 diagnosis and prognosis. The accuracy measures included the sensitivity, specificity, likelihood ratios, and diagnostic odds ratio (DOR) with their 95% confidence intervals (CIs). A higher DOR indicates a higher diagnostic accuracy. AUC values of ≥0.5, 0.75, 0.93, or 0.97 were considered to represent fair, good, very good, or excellent accuracy, respectively [26,27]. Moreover, we also constructed a hierarchical summary receiver operating curve (SROC).
We used mean difference (MD) to compare values of NLR across different groups. A fixed-effect method [28] was applied when there was no evidence of heterogeneity between studies, otherwise, a random-effects method was chosen [29,30]. The heterogeneity between studies was evaluated using Q statistic and $I^2$ test [29,31,32]; where P-value $= 0.1$ and/or $I^2 > 50\%$ indicating a significant heterogeneity [33,34]. The heterogeneity was explored using meta-regression, and sensitivity as well as subgroup analysis according to the potential covariates such as study design, risk of bias, percentage of the event (such as severe or lethal cases of COVID-19 infection), males’ per cent, the cutoff value of the NLR. The meta-regression has been used to explore between-study heterogeneity in meta-analysis studies aiming to incorporate the effect of the aforementioned covariates on summary measures of performance. Since the publication bias analysis is a concern for meta-analysis, it was conducted using the funnel plot and the Egger test [35]. We used the Midas command in Stata software version 12 [36] and Comprehensive Meta-analysis (CMA) software version 3 (Biostat, NJ, USA) for the analysis. A P-value $<0.05$ was considered significant.

3. Results

3.1. Search Results

Our search retrieved 291 articles, among which 74 duplicates were removed. The rest underwent abstract screening to yield 92 articles for full-text screening. Ultimately, a total of 32 articles with 8,120 individuals, including 7,482 COVID-19 patients, were included. Three articles were investigating the role of NLR in COVID-19 diagnosis, 2 in diagnosis and severity, 17 in severity, 4 in severity and mortality, 6 in mortality prediction only (Figure 1).

3.2. Studies and Patients’ Characteristics

There were 28 retrospective articles with a male percentage ranging from 37.3 to 69% with only one study including only females, and mean age ranging from 28.4 to 65 years (Table 1). All studies used PCR as an inclusion criterion except for Pascual Gómez et al. who had 74.2% of the patients as positive SARS-CoV-2 cases by PCR [37].

Figure 1. The PRISMA chart showing the flow of publications via the review process. Out of 291 articles, a total of 32 articles with 8,120 individuals, including 7,482 COVID-19 patients, were included.
3.3. Quality Assessment

Of the included articles, 27 were at low risk of bias, while only 5 were at high risk of bias (Table S2).

3.4. Quantitative Synthesis

3.4.1. Diagnosis

Patients with COVID-19 infection had significantly higher levels of NLR in comparison to negative individuals (MD [95% CI] = −1.48 [−1.74, −1.22], P-value < 0.001), with an estimated sensitivity and specificity of 62% [52, 72%] and 80% [62, 91%], respectively and DOR of 6.69 [3.66, 12.25]). The positive and negative likelihood ratios [95% CI] were 3.14 [1.74, 5.67] and 0.47 [0.4, 0.55], respectively, and the AUC was 0.73 [0.69, 0.76]. With no publication bias (P-value = 0.48).

3.5. Severity

Moderate and severe COVID-19 infected patients had significantly higher levels of NLR than mild and non-severely infected patients, (MD [95% CI] = −1.09 [−1.58, −0.59] and −7.14 [−8.67, −5.6], respectively), yet, there was a significant publication bias (P-value <0.009). The accuracy measures for predicting severity were sensitivity of 75% [69, 81%], specificity of 79% [72, 84%], DOR of 11.45 [7.74, 16.93] and AUC of 0.82 [0.78, 0.85] (Figures 2–4). The positive and negative likelihood ratios [95% CI] were 3.59 [2.74, 4.71] and 0.31 [0.25, 0.39], respectively, with a significant publication bias (P-value <0.001).


3.6. Mortality

Lethal cases of COVID-19 infection had significantly higher levels of NLR compared to non-lethal cases (MD [95% CI] of $16.1 [-27.24, -4.96], P-value = 0.005), with a sensitivity of 83% [75, 89%], specificity of 80% [71, 86%] and DOR of 18.69 [11.72, 29.81] (Table 2). The AUC [95% CI] was 0.88 [0.85, 0.91] and the positive and negative likelihood ratios [95% CI] were 4.05 [2.9, 5.64] and 0.22 [0.15, 0.31], respectively, with no publication bias (P-value = 0.78).

3.7. Sensitivity and subgroup analysis and meta-regression

Our sensitivity analysis, through removing one study each time, did not alter the results (Table 3). Of note, we used subgroup analysis and meta-regression to see the effect of covariates and heterogeneity on the accuracy of the NLR in diagnosis and prediction. It is worth mentioning that heterogeneity was found. However, setting the cutoff value of NLR to $\geq 3.63$ to predict COVID-19 severity was associated with lower sensitivity (70% [62–78%]) and higher specificity (86% [81–91%]) while high risk of bias studies had lower accuracy in mortality prediction (sensitivity = 77% [66–89%] and specificity = 76% [64–89%]) (Table S3).

4. Discussion

In this study, we found significantly higher levels of NLR in advanced stages compared to earlier stages of COVID-19 with good accuracy to diagnose and predict the disease, especially to predict mortality from COVID-19.

COVID-19 diagnosis relies primarily on SARS-CoV-2 detection via PCR. Yet, there are still numerous drawbacks including false-negative findings due to a low viral load and the relative shortage of detection kits [65]. A test with the ability to discern quickly and early COVID-19 is needed as a biomarker to help predict and prevent associated morbidity and mortality. It was also suggested that routine blood tests were more acceptable for screening individuals with asymptomatic or mild COVID-19 and may be used for screening in outbreak areas [66]. NLR is readily calculated and cost-effective such that clinicians can screen high-risk individuals earlier. This is especially desirable in settings experiencing healthcare resource scarcity. It was stated that the NLR was the most helpful independent prognostic biomarker in determining the COVID-19 resource and the treatment efficacy [13,22,67–70]. Besides, NLR had a higher diagnostic accuracy than other assessment tools such as the CURB-65 and MulBSTA scores [67]. It was demonstrated that procalcitonin does not enable clinicians to immediately decide if the infection is viral or bacterial and consequently if antibiotics are better to be administered or withheld [71]. Yet, the NLR is better compared to inflammatory markers including c-reactive protein or interleukin [13].

Acute respiratory distress syndrome (ARDS), featured by a rapid onset of generalized pulmonary inflammation, is the leading cause of death in SARS-CoV-2 patients. With this, elevated NLR reflecting an enhanced inflammation may suggest a poorer prognosis compared to those with lower NLR. Additionally, individuals with serious viral infection could have a bacterial co-infection due to their low immune response, resulting in an increased NLR [72]. The NLR elevation could occur due to dysregulation of inflammatory cytokine expression, an aberrant increase of pathological low-density neutrophils and up-regulation of genes involved in lymphocytic apoptosis [73–75]. Lymphocytes are also depleted as the virus is engulfed. Recent studies reported that the COVID-19 may primarily affect T-cells (particularly CD4+ and CD8+ T-cells) [76] but not absolute B-cell and natural killer (NK) cells [77]. The virus’ ability to infect T-cells through ACE-2 receptors and cluster of differentiation (CD)147-spike proteins is another mechanism [78]. The inflammatory response may trigger hyper-secretion of inflammatory cytokines including TNF-α and IL-6, leading to permanently high neutrophils. In contrast, catecholamines, cortisol, and the increased pro-inflammatory mediators will bind to lymphocytic surface receptors and subsequently initiate lymphocytic apoptosis, leading to lymphopenia [79], and clinical deterioration in COVID-19. The rise of pro-inflammatory cytokines with lymphopenia predisposes severe COVID-19 patients to cytokine storm, thus leading to more lymphocytic apoptosis and multi-organ failure [13,67,80,81].

The severity of pathologic injury during SARS or MERS correlates with the extensive infiltration of neutrophils in the lung and increased neutrophils in the peripheral blood [82]. The extent of

---

**Table 2:**

| Study name | Difference in means | Standard error | Lower limit | Upper limit | P-value | Non-severe | Severe |
|------------|--------------------|----------------|-------------|-------------|---------|------------|--------|
| Aqiel, JSE Pakistan | 6.270 | 1.440 | 4.509 | 7.909 | 0.000 | 57 | 36 |
| Hangiang, JSE China | -28.050 | 1.440 | -29.959 | -26.150 | 0.000 | 55 | 44 |
| Wang, JSE China | -4.750 | 0.525 | -5.830 | -3.671 | 0.000 | 52 | 27 |
| Zhang, JSE China | -5.050 | 0.673 | -5.630 | -4.480 | 0.000 | 50 | 46 |
| Liu, JSE China | 0.700 | 0.673 | 0.480 | 1.030 | 0.000 | 51 | 34 |
| Liu, JSE China | 0.670 | 0.673 | 0.480 | 1.030 | 0.000 | 51 | 34 |
| Liu, JSE China | 0.670 | 0.673 | 0.480 | 1.030 | 0.000 | 51 | 34 |
| Liu, JSE China | 0.670 | 0.673 | 0.480 | 1.030 | 0.000 | 51 | 34 |
| Liu, JSE China | 0.670 | 0.673 | 0.480 | 1.030 | 0.000 | 51 | 34 |
| Liu, JSE China | 0.670 | 0.673 | 0.480 | 1.030 | 0.000 | 51 | 34 |
| Liu, JSE China | 0.670 | 0.673 | 0.480 | 1.030 | 0.000 | 51 | 34 |

**Figure 4:** A meta-analysis of the association between the NLR and COVID-19 severity. Forest plot showing the pooled MD with its 95% CI using a random-effects model. The black diamond represents the pooled effect size. The figure shows that moderate and severe COVID-19 infected patients had significantly higher levels of NLR than mild and non-severely infected patients.
the increased neutrophils could therefore suggest the intensity of inflammatory responses in COVID-19. Bearing both of these issues in mind, the NLR may serve as a useful factor to reflect the intensity of imbalance of inflammation and immune responses in COVID-19, particularly seeing as how it drops upon improvement of the clinical condition [66,83].

Growing evidence has revealed that neutrophils exhibit both pathological and protective functions [84]. Neutrophil survival may be prolonged for several days after viral infection [85]. The prolonged activation of neutrophils leads to the production of pro-inflammatory mediators and toxins, which are harmful to cells [86,87]. Neutrophils constitute the nonspecific immunity that initiates the body’s responses to inflammation, whereas lymphocytes constitute the protective element against inflammation, indicate the extent of immune system impairment and are important for dampening overactive innate immune responses during viral infection [88].

Thus, lymphopenia may result in aggravated inflammatory processes while restoration of T-lymphocytes may alleviate them. Some studies have suggested that lymphopenia indicates that SARS-CoV-2 consumes many immune cells, inhibits the cellular immune function, and results in a reduced but hyper-activated peripheral T – lymphocytes; actions that partially account for the severe immune injury in COVID-19 [62].

Of note, we included missing data given by included article’s authors, conducted risk of bias evaluation, and provided sensitivity analysis by removing articles with a high risk of bias.

Our results are robust because our findings were the same in nearly all sensitivity and subgroup analyses where exclusion of studies with a poor QUADAS-2 assessment or a study with negative PCR for some of the included patients did not alter the conclusions [37]. Our analysis is however not without some limitations. The effect of heterogeneity may be low because most of the studies were in China. Additionally, it was unclear when in the disease course the NLR values were measured; depending on the severity of COVID-19 infection, NLR values may change during the disease course. Although the NLR had high accuracy, no unified cutoff is present, and its accuracy can be influenced by clinician experience. With this in mind, due diligence should be made while interpreting NLR findings in this context.

5. Expert Opinion

Laboratory biomarkers to forecast the severity of COVID-19 are essential in a pandemic because resource allocation must be carefully planned. NLR could help in assessing the allocation of respiratory equipment in ICU patients and early evaluation for those in need of ECMO. The close evaluation of COVID-19 severity and effective early interventions are key measures to reduce mortality. Indeed, it is strongly recommended that physicians should use a combination of readily available biomarkers to better diagnose and/or predict COVID-19 than depending on a single test. A prospective data collection

Table 1. Summary of characteristics of the included studies*.

| Author, year, country | Study design | Sample size | COVID-19 Cases/Severe/Died | Age, years* | Male, % | Risk of bias* |
|-----------------------|--------------|-------------|---------------------------|------------|--------|-------------|
| Anggraini, 2020, Indonesia [58] | Cross-sectional**| 9 | 9/ NR/0 | 28.44 | 0 | Low |
| Ashgar, 2020, Pakistan [59] | Retrospective | 100 | 100/ 33/22 | 52.58 | 69 | High |
| Chen, 2020, China [40] | Retrospective | 681 | 681/681/104/ | 65 | 53.2 | Low |
| Cheng, 2020, China [41] | Retrospective | 456 | 456/251/46 | 54.97 | 46.27 | Low |
| Hongbing, 2020, China [72] | Retrospective | 93 | 93/43/31 | 62.07 | 59.1 | Low |
| Huang, 2020, China [42] | Retrospective | 415 | 415/29/NR | 44 | 52.3 | Low |
| Huan, 2020, China [43] | Retrospective | 344 | 344/45/15 | 52.9 | 54.7 | Low |
| Hui, 2020, China [60] | Retrospective | 84 | 84/NR/42 | 66.5 | 66.7 | Low |
| Liu, 2020, China [61] | Prospective | 115 | 115/37/0 | 42.5** | 55.7 | Low |
| Liu, 2020, China [62] | Retrospective | 40 | 40/13/3 | 48.7 | 37.5 | Low |
| Liu, 2020, China [55] | Retrospective | 84 | 84/43/5 | 53 | 56 | Low |
| Liu, 2020, China [63] | Retrospective | 134 | 134/19/0 | 51.5 | 47 | High |
| Long, 2020, China [70] | Prospective | 301 | 301/66/17 | 51 | 49.8 | Low |
| Shi, 2020, China [64] | Retrospective | 723 | 696/63/NR | 45.27 | 52.1 | Low |
| Mingming, 2020, China [49] | Retrospective | 72 | 72/20/NR | 58.01 | 44.4 | Low |
| Nalbant, 2020, Turkey [56] | Retrospective | 80 | 54/NR/NR | 55.3 | 51 | Low |
| Ok, 2020, Turkey [45] | Retrospective | 139 | 139/54/13 | 55.5 | 44.6 | Low |
| Pascual Gómez, 2020, Spain [37] | Retrospective | 163 | 163/NR/33 | 64.75 | 49.7 | High |
| Peng, 2020, China [52] | Retrospective | 485 | 190/31/NR | 46.64 | 48.7 | Low |
| Rocio, 2020, Spain [53] | Prospective | 501 | 501/42/36 | 52 | 63.3 | High |
| Shang, 2020, China [46] | Retrospective | 443 | 443/139/NR | 56 | 49.7 | Low |
| Sun, 2020, China [47] | Retrospective | 116 | 116/27/NR | 54.5** | 51.7 | Low |
| Tan, 2020, China [48] | Retrospective | 102 | 27/6/two | 39.2** | 37.3 | Low |
| Tatum, 2020, USA [57] | Retrospective | 125 | 125/16/23 | 58.7 | 45.6 | High |
| Wang, 2020, China [58] | Retrospective | 45 | 45/10/NR | 39 | 51.1 | Low |
| Xiao, 2020, China [69] | Retrospective | 442 | 442/103/19 | NR | 50.2 | Low |
| Xie, 2020, China [60] | Retrospective | 324 | 109/12/1 | 50.25** | 54.2 | Low |
| Xintian, 2020, China [59] | Retrospective | 63 | 63/31/NR | 62.25 | 52.4 | Low |
| Yan, 2020, China [61] | Retrospective | 1,004 | 1004/66/40 | 65** | 49.1 | Low |
| Yang, 2020, China [62] | Retrospective | 93 | 93/24/NR | 46.4 | 60.2 | Low |
| Zhang, 2020, China [63] | Retrospective | 177 | 177/24/NR | 44.13 | 55.9 | Low |
| Zhang, 2020, China [64] | Retrospective | 167 | 167/31/0 | 46 | 60 | Low |

Abbreviations; NR. *Mean or median as reported by the included study. **This is the mean of two reported values for two groups as reported by the included study.

*According to the QUADAS-2 tool recommendations, if a study is judged as ‘low’ on all domains relating to bias or applicability, then it is appropriate to have an overall judgment of ‘low risk of bias’ or ‘low concern regarding applicability’ for that study while if a study is judged ‘high’ or ‘unclear’ in one or more domains, then it may be judged ‘at risk of bias’ or as having ‘concerns regarding applicability’ [25].
Table 2. The summary estimates of the diagnostic and prognostic role of NLR in COVID-19.

| Prediction | Studies/individuals number | Sensitivity, 95% CI | Specificity, 95% CI | DOR, 95% CI | LR, 95% CI | AUC, 95% CI | P-value of heterogeneity | P-value of publication bias |
|------------|-----------------------------|---------------------|---------------------|-------------|-------------|-------------|-------------------------|-----------------------------|
| Diagnosis  | 5/885                       | 62 [52, 72]         | 80 [62, 91]         | 6.69 [3.66, 12.25] | 3.14 [1.74, 5.67] | 0.47 [0.4, 0.73] | 0.69 [0.69, 0.76] | <0.001                     | 0.48                        |
| Severity   | 24/8,845                    | 75 [69, 81]         | 79 [72, 84]         | 11.45 [7.74, 16.93] | 3.59 [2.74, 4.71] | 0.31 [0.25, 0.39] | 0.78 [0.78, 0.85] | <0.001                     | <0.001                     |
| Mortality  | 10/3,333                    | 83 [75, 89]         | 80 [71, 86]         | 18.69 [11.72, 29.81] | 4.05 [2.9, 5.64] | 0.22 [0.15, 0.31] | 0.88 [0.85, 0.91] | <0.001                     | 0.78                        |

Abbreviations: CI = confidence interval, DOR = diagnostic odds ratio, LR = likelihood ratio.

Table 3. The summary estimates of comparisons between negative control and different COVID-19 groups.

| Comparison                  | Studies | Number of individuals | MD (95% CI) | P-value | I² (%) | Egger's 2-tailed bias p-value | Largest p-value after removing any single study |
|----------------------------|---------|-----------------------|-------------|---------|--------|-------------------------------|-----------------------------------------------|
| Negative versus positive SARS-CoV-2 groups | 4       | 392/394               | −1.48 [−1.74, −1.22] | <0.001 | 0.817 | 0 -                            | <0.001                                       |
| Mild versus Moderate       | 2       | 103/605               | −1.09 [−1.58, −0.59] | <0.001 | 0.319 | 0 -                            | <0.001                                       |
| Non-severe versus Severe   | 18      | 2,780/675             | −7.14 [−8.67, −5.6] | <0.001 | <0.001 | 95.4 0.009                    | <0.001                                       |
| Survived versus Died       | 7       | 2,380/290             | −15.04 [−23.92, −6.16] | 0.001 | <0.001 | 99.1 -                        | 0.034                                        |

Abbreviations: CI = confidence interval, MD = mean difference, LR = likelihood ratio. Significant differences are in bold.

with a multi-variable prediction model is required to derive a robust score for COVID-19 diagnosis and prediction.

Acknowledgments

We would like to thank all authors of the included studies who helped us in this study by providing us with the missing raw data that allowed us to complete the analysis and make the study more rigorous.

Prospero Registration ID: CRD42020201117.

- Question: What is the diagnostic and prognostic accuracy of neutrophil-to-lymphocyte ratio (NLR) in COVID-19?

- Finding: We found significantly higher levels of NLR in advanced stages compared to earlier stages of COVID-19 with good accuracy to diagnose and predict the disease, especially to predict the mortality from COVID-19.

- Meaning: NLR could help in assessing the resource allocation in severe COVID-19 patients even in restricted settings.

Funding

This paper was not funded.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Availability of data and material

The dataset supporting the conclusions of this article is included within the article (and its additional files).

Authors’ contributions

AAAMMA: this author helped in developing the idea, designing the study, writing the protocol, searching the databases, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

MGK: this author helped in developing the idea, designing the study, writing the protocol, searching the databases, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

MKH: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

EMF: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

HMY: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

ME: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

AAN: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

MW: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

FAA: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

HZA: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

MAY: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

AP: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.
MH: this author helped in writing the protocol, screening, data extraction, writing, and reviewing the manuscript and approving the final version.

Supplementary material
Supplemental data for this article can be accessed here.

ORCID
Ahmed Abdelaal Ahmed Mahmoud M. Alkhatif
http://orcid.org/0000-0002-0473-9764
Mohamed Gomaa Kamel
http://orcid.org/0000-0001-9848-2965
Fatma Abd-Elsahed Abd-Elhay
http://orcid.org/0000-0002-5928-6731

References
1. 2009 H1N1 Pandemic (H1N1pdm09 virus) | Pandemic Influenza (Flu) | CDC. https://www.cdc.gov/flu/pandemic-resources/2009-h1n1-pandemic.html (accessed April 9, 2020).
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
3. Elgamsy S, Kamel MG, Ghozy S, et al. First case of focal epilepsy associated with SARS-coronavirus-2. J Med Virol. 2020. DOI:10.1002/jmv.26113
4. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683.
5. Elgamsy S, Sakr ES, Kamel MG, et al. Epidemiologic features and clinical course of COVID-19: a retrospective analysis of 19 patients in Germany. Future Virol. 2021. DOI:10.2217/fvl-2020-0256
6. Elhusseiny KM, Abd-Elsahed Abd-Elhay F, Kamel MG. Possible therapeutic agents for COVID-19: a comprehensive review. Expert Rev Anti Infect Ther. 2020;18(10):1005–1020.
7. Zhang C, Wu Z, Li J-W, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954.
8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
9. Ciaccio M, Aghello L. Biochemical biomarkers alterations in coronavirus disease 2019 (COVID-19). Diagnosis. 2020 Nov 18;7(4):365-372.
10. Henry BM, De Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–1028.
11. Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399.
12. Xia X-Y, Wu J, Liu H-L, et al. Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19. J Clin Virol. 2020;127:104360.
13. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768.
14. Hai L, Hu Z-D. The clinical utility of neutrophil to lymphocyte ratio in pregnancy related complications: a mini-review. Journal of Laboratory and Precision Medicine. 2020;5:1-1.
15. Aghello L, Bivona G, Vidali M, et al. Monocyte distribution width (MDW) as a screening tool for sepsis in the Emergency Department. Clin Chem Lab Med. 2020;58(11):1951–1957.
16. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11(1):35–59.
17. Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood count parameters in cardiovascular diseases: an early indicator of prognosis? Exp Mol Pathol. 2019;110:104267.
18. Huang Z, Fu Z, Huang W, et al. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: a meta-analysis. Am J Emerg Med. 2020 Mar;38(3):641–647.
19. Takada T, Hoogland J, Yano T, et al. Added value of inflammatory markers to vital signs to predict mortality in patients suspected of severe infection. Am J Emerg Med. 2020;38(7):1389–1395.
20. Chen J-L, Wu J-N, Lv X-D, et al. The value of red blood cell distribution width, neutrophil-to-lymphocyte ratio, and hemoglobin-to-red blood cell distribution width ratio in the progression of non-small cell lung cancer. PLoS One. 2020;15(8):e0237947.
21. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol. 2020;92(10):1733–1734.
22. Han Q, Wen X, Wang L, et al. Role of hematological parameters in the diagnosis of influenza virus infection in patients with respiratory tract infection symptoms. J Clin Lab Anal. 2020;34(5):e23191.
23. Tajiri K, Baba H, Kawai K, et al. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol. 2016;31(7):1291–1299.
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
25. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536.
26. Jones CM, Athanassiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79(1):16–20.
27. Sallam A, Alkhatif AAAM, Kamel MG, et al. The diagnostic accuracy of noninvasive methods to measure the intracranial pressure: a systematic review and meta-analysis. Anesth Analg. 2020;131(4):1281–1290.
28. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–748.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
30. Alkhatif AAAM, Kamel MG, Farag EM, et al. Deep hypothermic circulatory arrest in the pediatric population undergoing cardiac surgery with electroencephalography monitoring: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2021. DOI:10.1053/j.jvca.2021.01.039
31. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557.
32. Sherif NA, Zayan AH, Eldaky AH, et al. Mast cell mediators in relation to dengue severity: a systematic review and meta-analysis. Rev Med Virol. 2020;30(1):e2084.
33. Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 2008;61(7):634–645.
34. Munafò MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20(9):439–444.
35. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
36. Dwamena B, Sylvester R, Carlos R midas: meta-analysis of diagnostic accuracy studies. Available at) (Accessed on 2017 Feb 8) http://fmwww.bc.edu/repec/bocode/m/midas.pdf View in Article. 2009.
37. Pascual Gomez NF, Monge Lobo I, Granero Cremadas I, et al. Potential biomarkers predictors of mortality in COVID-19 patients in the emergency department. Revista española de quimioterapia: publicacion oficial de la Sociedad Española de Quimioterapia. Revista Española de Quimioterapia. 2020;33(4):267–273.

38. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82–92.

39. Asghar MS, Kazmi SJH, Khan NA, et al. Clinical profiles, characteristics, and outcomes of the first 100 admitted COVID-19 patients in pakistan: a single-center retrospective study in a tertiary care hospital of karachi. Cureus. 2020;12:6.

40. Chen F-F, Zhong M, Liu Y, et al. The characteristics and outcomes of 681 severe cases with COVID-19 in China. J Crit Care. 2020;60:32–37.

41. Cheng B, Hu J, Zuo X, et al. Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort. Clin Microbiol Infect. 2020;26(10):1400–1405.

42. Li H, Zhao M, Xu Y. Biochemical analysis between common type and critical type of COVID-19 and clinical value of neutrophil/lymphocyte ratio. Journal of Southern Medical University. 2020;40(7):965–971.

43. Huang S, Huang M, Li X, et al. Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio for predicting clinical outcomes in COVID-19. medRov. 2020;2020(2005):20090431.

44. Huang J, Cheng A, Lin S, et al. Individualized prediction nomograms for disease progression in mild COVID-19. J Med Virol. 2020;92(10):2074–2080.

45. Hui S, Tao B, Jiaheng S, et al. Predictive value of multiple inflammatory indexes on the prognosis of patients with corona virus disease 2019. Practical Journal of Cardiac Cerebral and Vascular Disease. 2020;6(28):13–16.

46. Liu Y-P, Li G-M, He J, et al. Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study. Ann Transl Med. 2020;8(10):10.

47. Liu F, Zhang Q, Huang C, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10(12):5613.

48. Shi N, Ma Y, Fan Y, et al. Predictive value of the neutrophil-to-lymphocyte ratio (nlr) for diagnosis and worse clinical course of the COVID-19: findings from ten provinces in China. SSRN Electronic Journal. 2020. DOI:10.2139/ssrn.3569838

49. Fei M, Tong F, Tao X, et al. Value of neutrophil-to-lymphocyte ratio in the classification diagnosis of coronavirus disease 2019. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32(5):554–558.

50. Nalbant A, Kaya T, Varim C, et al. Can the neutrophil/lymphocyte ratio (NLR) have a role in the diagnosis of coronavirus 2019 disease (COVID-19)? Revista da Associaçao Medica Brasileira (1992). 2020 Jun;56(6):746-751.

51. Ok F, Erdogan O, Durmus E, et al. Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID-19 patients. J Med Virol. 2020;93(2):786–793.

52. Peng J, Qi D, Yuan G, et al. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): a multicenter, cross-sectional study. J Clin Lab Anal. 2020;34(10). DOI:10.1002/jcla.23475

53. Rocío LG, Alberto UR, Paloma T, et al. Interleukin-6-based mortality risk model for hospitalised COVID-19 patients. J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9.

54. Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92(10):2188–2192.

55. Sun S, Cai X, Wang H, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta. 2020;507:174–180.

56. Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92(7):856–862.

57. Tatum D, Taghavi S, Houghton A, et al. Neutrophil-to-lymphocyte ratio and outcomes in louisiana covid-19 patients. Shock. 2020;54(5):652–658.

58. Wang C, Deng R, Gou L, et al. Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters. Ann Transl Med. 2020;8(9):593.

59. Xiao L-S, Zhang W-F, Gong M-C, et al. Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019. EBioMedicine. 2020;57:102880–102880.

60. Xie G, Ding F, Han L, et al. The role of peripheral blood eosinophil counts in COVID-19 patients. Allergy: Eur J Allergy Clin Immunol. 2021 Feb;76(2):471-482.

61. Yan X, Li F, Wang X, et al. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: a retrospective cross-sectional study. J Med Virol. 2020;92(11):2573–2581.

62. Yang A-P, Liu J-P, Tao W-Q, et al. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.

63. Zhang M, Xiao E, Liu J, et al. An emerging marker predicting the severity of COVID-19: neutrophil-lymphocyte count ratio. 2020.

64. Zhang Y, Wu W, Du M, et al. Neutrophil-to-lymphocyte ratio may replace chest computed tomography to reflect the degree of lung injury in patients with corona virus disease 2019 (COVID-19). 2020.

65. Song C-Y, Xu J, He J-Q, et al. COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients. MedRxiv. 2020.

66. Anggraini WWP, Sulistyawati S. Low neutrophil-to-lymphocyte ratio decreases risk of coronavirus disease in pregnant women. Universa Medicina. 2020;39(2):88–96.

67. Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):1–12.

68. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6–e12.

69. Xia X, Wen M, Zhan S, et al. An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19. Nan fang yi ke da xue xue bao: Journal of Southern Medical University. 2020;40(3):333–336.

70. Long L, Zeng X, Zhang X, et al. Short-term outcomes of COVID-19 and risk factors for progression. Eur Respir J. 2020;55(5):5.

71. Kamat IS, Ramachandran V, Erwaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538–542.

72. Chen H, Guo J, Wang C, et al. Clinical characteristics and intravenous vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–815.

73. Yan Q, Li P, Ye X, et al. Longitudinal peripheral blood transcriptional analysis of COVID-19 patients captures disease progression and reveals potential biomarkers. medRxiv. 2020. DOI:10.1101/2020.11.03.20225250

74. Azar MM, Shin JJ, Kang I, et al. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome. Expert Rev Mol Diagn. 2020 Nov;20(11):1087-1097.

75. Saghazadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus—a perspective. Expert Rev Clin Immunol. 2020;16(1):1–6.

76. Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate forms of coronavirus disease. J Clin Invest. 2019 May 1;130(5):2620-2629
77. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.

78. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;270–273.

79. Almeida MQ, Mendonca BB. Adrenal insufficiency and glucocorticoid use during the COVID-19 pandemic. Clinics. 2020;75:75.

80. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):S5.

81. Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):S5.

82. Channappanavar R, Perlman S Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Paper presented at: Seminars in immunopathology2017.

83. Pereira A, Cruz-Melguizo S, Adrien M, et al. Clinical course of coronavirus disease-2019 (COVID-19) in pregnancy. Acta Obstet Gynecol Scand. 2020;99(7):839–847.

84. Drescher B, Bai F. Neutrophil in viral infections, friend or foe? Virus Res. 2013;171(1):1–7.

85. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med. 2011;17(3–4):293–307.

86. Tate MD, Brooks AG, Reading PC. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir Res. 2008;9(1):1–13.

87. Tumpey TM, Garcia-Sastre A, Taubenberger JK, et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol. 2005;79(23):14933–14944.

88. Kim KD, Zhao J, Auh S, et al. Adaptive immune cells temper initial innate responses. Nat Med. 2007;13(10):1248–1252.